{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:35:56Z","timestamp":1792316156801,"version":"4.4.0"},"reference-count":63,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"Georgia Cancer Coalition Distinguished Scientist Award and Cancer Research","award":["R21 CA158686-01A1"],"award-info":[{"award-number":["R21 CA158686-01A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Hematol. Oncol."],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.2217\/ijh.12.7","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T18:55:06Z","timestamp":1349895306000},"page":"35-45","source":"Crossref","is-referenced-by-count":10,"title":["Initial Management Strategies for Follicular Lymphoma"],"prefix":"10.2217","volume":"1","author":[{"given":"Qiushi","family":"Chen","sequence":"first","affiliation":[{"name":"H Milton Stewart School of Industrial & Systems Engineering , Georgia Institute of Technology, Atlanta, GA30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[{"name":"H Milton Stewart School of Industrial & Systems Engineering , Georgia Institute of Technology, Atlanta, GA30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miray","family":"Seward","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R","family":"Flowers","sequence":"additional","affiliation":[{"name":"H Milton Stewart School of Industrial & Systems Engineering , Georgia Institute of Technology, Atlanta, GA30332, USA"},{"name":"Department of Hematology\/Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA30322, USA"},{"name":"Bone Marrow & Stem Cell Transplantation, 1365 Clifton Road, NE Building C, Suite 3006, Emory University, Atlanta, GA30322, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,9,24]]},"reference":[{"issue":"6","key":"e_1_3_2_3_1","first-page":"393","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"Flowers CR","year":"2010","unstructured":"Flowers CR , SinhaR, Vose.JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J. Clin.60(6), 393\u2013408 (2010).","journal-title":"CA Cancer J. Clin."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.213"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01747-3"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6546"},{"issue":"1","key":"e_1_3_2_8_1","first-page":"19","article-title":"Risk-adapted treatment of follicular non-Hodgkin lymphoma: current standards and future strategies","volume":"92","author":"Dreyling M","year":"2007","unstructured":"Dreyling M , BuskeC, UnterhaltM, HiddemannW. Risk-adapted treatment of follicular non-Hodgkin lymphoma: current standards and future strategies. Haematologica92(Extra 1), 19\u201324 (2007).","journal-title":"Haematologica"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.303"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2004.09.001"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.013"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Federico M LuminariS DondiAet al. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). ASCO Meeting Abstracts 30 Abstract 8006 (2012).","DOI":"10.1200\/jco.2012.30.15_suppl.8006"},{"issue":"4","key":"e_1_3_2_19_1","first-page":"022","article-title":"Impact of induction chemotherapy regimen on response, safety and outcome in the Prima Study.","volume":"22","author":"Morschhauser F","year":"2011","unstructured":"Morschhauser F , SeymourJ, FeugierPet al. Impact of induction chemotherapy regimen on response, safety and outcome in the Prima Study. Ann. Oncol. 22(Suppl. 4), 022 (2011).","journal-title":"Ann. Oncol."},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Nastoupil L SinhaR ByrtekMet al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Blood 118(21) Abstract 97 (2011).","DOI":"10.1182\/blood.V118.21.97.97"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.086"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22066"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23236"},{"issue":"2","key":"e_1_3_2_26_1","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young RC","year":"1988","unstructured":"Young RC , LongoDL, GlatsteinE, IhdeDC, JaffeES, DeVitaVTJr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol.25(2 Suppl. 2), 11\u201316 (1988).","journal-title":"Semin Hematol."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-90-1-10"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"issue":"2","key":"e_1_3_2_29_1","first-page":"213","article-title":"Follicular lymphoma: expanding therapeutic options","volume":"19","author":"Ganti AK","year":"2005","unstructured":"Ganti AK , BociekRG, BiermanPJ, EnkeCA, VoseJM, ArmitageJO. Follicular lymphoma: expanding therapeutic options. Oncology19(2), 213\u2013228 (2005).","journal-title":"Oncology"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8508"},{"issue":"2","key":"e_1_3_2_31_1","first-page":"176","article-title":"Improving our use and understanding of antibodies in B-cell lymphomas the Ujjani\/Cheson article reviewed","volume":"24","author":"Flowers CR","year":"2010","unstructured":"Flowers CR . Improving our use and understanding of antibodies in B-cell lymphomas the Ujjani\/Cheson article reviewed. Oncology (Williston Park)24(2), 176\u2013177 (2010).","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.034"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.052"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Ardeshna KM QianW SmithPet al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II III IV asymptomatic non-bulky follicular lymphoma (grades 1 2 and 3a). A preliminary analysis. Blood 116(21) Abstract 6 (2010).","DOI":"10.1182\/blood.V116.21.6.6"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Sinha R ByrtekM DeJoubnerNet al. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Blood 118(21) Abstract 775 (2011).","DOI":"10.1182\/blood.V118.21.775.775"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Kahl B FangxinH Williamset al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 118 Abstract LBA-6 (2011).","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","unstructured":"Fowler N SharmanJP SmithSMet al. The Btk inhibitor PCI-32765 induces durable responses with minimal toxicity in patients with relapsed\/refractory b-cell malignancies: results from a Phase I study. Blood 116 Abstract 964 (2010).","DOI":"10.1182\/blood.V116.21.964.964"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Kahl B ByrdJS FlinnIWet al. Clinical safety and activity in a Phase 1 study of CAL-101 an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 116 Abstract 1777 (2010).","DOI":"10.1182\/blood.V116.21.1777.1777"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08966.x"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Leonard J JungS JohnsonJL BartlettN BlunKA ChesonBD. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. ASCO Metting Abstracts 30 Abstract 8000 (2012).","DOI":"10.1200\/jco.2012.30.15_suppl.8000"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08065.x"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Nooka AK NabhanC ZhouXet al. Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): a U.S. patient cohort treated predominantly in community practices. Ann. Oncol. (2012) (In Press).","DOI":"10.1093\/annonc\/mds429"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2003.00234.x"},{"key":"e_1_3_2_45_1","first-page":"17","volume-title":"Proceedings of the 31st Annual Meeting of the Society for Medical Decision Making","author":"Ayer T","unstructured":"Ayer T , AlagozO, ToutN. A mathematical model to optimize breast cancer screening policy. Proceedings of the 31st Annual Meeting of the Society for Medical Decision Making. 17\u201321October 2009 (Abstract 4751)."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1287\/opre.1100.0877"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1145\/1315575.1315579"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm086"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.1040.0287"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1287\/opre.1060.0329"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0933-3657(99)00042-1"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1287\/opre.1070.0480"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(11)70023-6"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.062606.122232"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00946-X"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.02.001"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.10.020"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:PREV.0000037641.26017.00"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00389"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.01.005"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10994-010-5229-0"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq184"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_3_2_64_1","doi-asserted-by":"crossref","unstructured":"Colombat P BrousseN MorschhauserF Franchi-RezguiP. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years. Blood 108(11) Abstract 486 (2006).","DOI":"10.1182\/blood.V108.11.486.486"},{"key":"e_1_3_3_2_1","unstructured":"Zelenetz AD et al.\n (2012): NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin\u2019s lymphoma v.2.2012. www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"}],"container-title":["International Journal of Hematologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/ijh.12.7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:31:53Z","timestamp":1715985113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/ijh.12.7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,24]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.2217\/ijh.12.7"],"URL":"https:\/\/doi.org\/10.2217\/ijh.12.7","relation":{},"ISSN":["2045-1393","2045-1407"],"issn-type":[{"value":"2045-1393","type":"print"},{"value":"2045-1407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,24]]}}}